[1]
|
Gross, J.L., de Azevedo, M.J., Silveiro, S.P., Canani, L.H., Caramori, M.L. and Zelmanovitz, T. (2005) Diabetic nephropathy: Diagnosis, prevention, and treatment. Diabetes Care, 28, 164-176. doi:10.2337/diacare.28.1.164
|
[2]
|
Luan, F.L. and Samaniego, M. (2010) Transplantation in diabetic kidney failure patients: Modalities, outcomes, and clinical management. Seminars in Dialysis, 23, 198-205. doi:10.1111/j.1525-139X.2010.00708.x
|
[3]
|
Lithovius, R., Harjutsalo, V., Forsblom, C. and Groop, P.H. and FinnDiane Study Group (2011) Cumulative cost of prescription medication in outpatients with type 1 diabetes in Finland. Diabetologia, 54, 496-503.
doi:10.1007/s00125-010-1999-y
|
[4]
|
Salonen, T., Reina, T., Oksa, H., Sintonen, H. and Pasternack, A. (2003) Cost analysis of renal replacement therapies in Finland. American Journal of Kidney Diseases, 42, 1228-1238. doi:10.1053/j.ajkd.2003.08.024
|
[5]
|
Wolfe, R.A., Ashby, V.B., Milford, E.L., et al. (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. New England Journal of Medcine, 341, 1725-1730.
doi:10.1056/NEJM199912023412303
|
[6]
|
Kho, M., Cransberg, K., Weimar, W. and van Gelder, T. (2011) Current immunosuppressive treatment after kidney transplantation. Expert Opin Pharmacother, 12, 1217-1231. doi:10.1517/14656566.2011.552428
|
[7]
|
National Institute for Clinical Excellence (2005) TA85: Renal transplantation—Immunosuppressive regimens (adults). The clinical effectiveness and cost-effectiveness of immunesuppressive therapy for renal transplantation. Nice, London. www.nice.org.uk/TA85guidance.
|
[8]
|
Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. American Journal of Transplantation, 9, S1-S155.
doi:10.1111/j.1600-6143.2009.02834.x
|
[9]
|
Jurgensen, J.S., Arns, W. and Hass, B. (2010) Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: A model approach. The European Journal of Health Economics, 11, 15-25.
doi:10.1007/s10198-009-0148-3
|
[10]
|
Mao, P.C., Lee, E.K. and Tseng, P.L. (2012) Trends in the use of immunosuppressive agents by outpatients after renal transplantation at a medical center in southern Taiwan. Transplantation Proceedings, 44, 185-189.
doi:10.1016/j.transproceed.2011.11.003
|
[11]
|
Gentil, M.A., Cantarell, A.C., Gonzalez, R.F.M., Marco, F.J.E., Lopez, De M.M.M. (2004) Impact of the new drugs in the cost of maintenance immunosuppression of renal transplantation. Is it justified? Nephrology Dialysis Transplantation, 19, 77-82. doi:10.1093/ndt/gfh1021
|
[12]
|
Joyce, A.T., Iacoviello, J.M., Nag, S., et al. (2004) Endstage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care, 27, 2829-2835. doi:10.2337/diacare.27.12.2829
|
[13]
|
Thorn, L.M., Forsblom, C., Fagerudd, J., et al. (2005) Metabolic syndrome in type 1 diabetes: Association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care, 28, 2019-2024.
doi:10.2337/diacare.28.8.2019
|
[14]
|
Littell, R.C. (2006) SAS for mixed models. SAS Institute, Cary.
|
[15]
|
Srinivas, T.R. and Meier-Kriesche, H.U. (2008) Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result. Clinical Journal of the American Society of Nephrology, 3, S101-S116. doi:10.2215/CJN.03510807
|
[16]
|
Galliford, J. and Game, D.S. (2009) Modern renal transplantation: Present challenges and future prospects. Postgraduate Medical Journal, 85, 91-101.
doi:10.1136/pgmj.2008.070862
|
[17]
|
Steiner, R.W. and Awdishu, L. (2011) Steroids in kidney transplant patients. Seminars in Immunopathology, 33, 157-167. doi:10.1007/s00281-011-0259-7
|
[18]
|
Denton, M.D., Magee, C.C. and Sayegh, M.H. (1999) Immunosuppressive strategies in transplantation. Lancet, 353, 1083-1091. doi:10.1016/S0140-6736(98)07493-5
|
[19]
|
Jardine, A.G., Gaston, R.S., Fellstrom, B.C. and Holdaas, H. (2011) Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet, 378, 1419-1427.
doi:10.1016/S0140-6736(11)61334-2
|
[20]
|
Salmela, K.T. and Kyllonen, L.E. (2004) Two decades of experience with cyclosporine in renal transplantation in Helsinki. Transplantation Proceedings, 36, 94S-98S.
doi:10.1016/j.transproceed.2004.01.036
|
[21]
|
European Mycophenolate Mofetil Cooperative Study Group (1995) Anonymous placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet, 345, 1321-1325.
|
[22]
|
Clayton, P.A., McDonald, S.P., Chapman, J.R. and Chadban, S.J. (2012) Mycophenolate versus azathioprine for kidney transplantation: A 15-year follow-up of a randomized trial. Transplantation, 94, 152-158.
doi:10.1097/TP.0b013e31825475a3
|
[23]
|
Meier-Kriesche, H.U., Li, S., Gruessner, R.W., et al. (2006) Immunosuppression: Evolution in practice and trends, 1994-2004. American Journal of Transplantation, 6, 1111-1131. doi:10.1111/j.1600-6143.2006.01270.x
|
[24]
|
Grinyo, J.M. and Cruzado, J.M. (2009) Mycophenolate mofetil and calcineurin-inhibitor reduction: Recent progress. American Journal of Transplantation, 9, 2447-2452. doi:10.1111/j.1600-6143.2009.02812.x
|
[25]
|
Vincenti, F., Jensik, S.C., Filo, R.S., Miller, J. and Pirsch, J. (2002) A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation, 73, 775-782. doi:10.1097/00007890-200203150-00021
|
[26]
|
Liefeldt, L. and Budde, K. (2010) Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transplant International, 23, 1191-1204.
|
[27]
|
Isoniemi, H. and Jalanko, H. (2004) Selection of organ transplant drugs is increasing. Duodecim, 120, 1371-1378.
|
[28]
|
Woodroffe, R., Yao, G.L., Meads, C., et al. (2005) Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technology Assessment, 9, 1-179.
|
[29]
|
Levy, G.A. (2010) Progress in transplantation. Journal of Therapeutic Drug Monitoring, 32, 246-249.
doi:10.1097/FTD.0b013e3181dca981
|
[30]
|
Daratha, K.B., Short, R.A., Corbett, C.F., et al. (2012) Risks of subsequent hospitalization and death in patients with kidney disease. Clinical Journal of the American Society of Nephrology, 7, 409-416.
doi:10.2215/CJN.05070511
|